Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule <sup>68</sup>Ga-ABY-025 in Breast Cancer Patients
Mattias Sandström(Uppsala University Hospital), Mark Lubberink(Uppsala University), Joachim Feldwisch(Uppsala University), Henrik Lindman(Uppsala University), Anders Wennborg(Affibody (Sweden)), Irina Velikyan(Uppsala University), Dan Sandberg(Uppsala University), Vladimir Tolmachev(Uppsala University), Jens Sørensen(Uppsala University), K. Lindskog(Uppsala University), Jörgen Carlsson(Uppsala University Hospital), Anna Orlova(Uppsala University)
Cited by 111
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Prospective of <sup>68</sup>Ga-Radiopharmaceutical Development
|Theranostics|2014|306
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260